Depression of hepatic gluconeogenesis by acute lead administration.
D000409:Alanine / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002250:Carbon Radioisotopes; D005215:Fasting; D005943:Gluconeogenesis / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D005949:Glucose Oxidase; D006943:Hyperglycemia / Q000175:diagnosis; D007275:Injections, Intravenous; D007854:Lead / Q000008:administration & dosage / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism; D008297:Male; D011773:Pyruvates / Q000378:metabolism; D051381:Rats
D001786:Blood Glucose; D002250:Carbon Radioisotopes; D011773:Pyruvates; D007854:Lead; D005949:Glucose Oxidase; D005947:Glucose; D000409:Alanine